Graffinity Enters into Drug Discovery Research Collaboration with Genentech
16-Oct-2009
- Germany
Graffinity Pharmaceuticals GmbH announced that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group. With this collaboration Genentech will gain access to Graffinity’s proprietary, fragment-based drug discovery technology.
Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Researchers grow cells in 'paper organs'
Fat metabolizing hormone studied in humans
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Reprogrammed fat cells support tumor growth
Off the shelf, on the skin - Stick-on electronic patches for health monitoring
New receptor found on scavenger cells - How adenoviruses invade the immune system of mice
Fusion Protein rFlaA:Betv1 Induces Regulatory B Cells and Thus Suppresses Allergic Processes - The fusion protein is a promising candidate for the treatment of birch pollen allergies
European Commission authorizes EU-wide marketing and distribution of Biofrontera's Ameluz
Piramal Pharma Solutions Names John Fowler as its Chief Operating Officer
Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease
